INTRODUCTION {#S5}
============

Trichopoulos proposed in 1990 that breast cancer might originate *in utero* ([@R20]). This hypothesis is supported by epidemiological studies showing a strong association between breast cancer risk and various birth phenotypes such as birth weight, birth length, and gestational age as reviewed by Michels and Xue ([@R11]). One of the speculated mechanisms underlying the relationship between birth outcomes and breast cancer risk is the possible influence of maternal environment on epigenetic regulation, such as changes in DNA methylation of the insulin-like growth factor-2 (*IGF2)* gene ([@R11]).

*IGF2* is an imprinted gene in which methylation silences the maternal allele resulting in only one parental allele (the paternal allele) to be expressed. Loss of imprinting (LOI) of *IGF2* leads to biallelic expression and increases production of IGF2. In the transgenic mouse model, overexpression of *IGF2* can induce mammary cancer ([@R1]). Human studies have found increased *IGF2* expression in both breast tumors([@R23]; [@R28]) and other breast lesions ([@R10]). *IGF2* expression is known to be an essential determinant of fetal growth ([@R15]; [@R18]). It is plausible that LOI of *IGF2* may result in high intrauterine expression of IGF2, which increases the number of susceptible stem cells in the mammary gland or enhances breast cell transformation *in utero*, prior to puberty when the tissues are very sensitive to carcinogenic insults ([@R11]). LOI of *IGF2* (DNA hypomethylation) has only been investigated in adults, but no studies have evaluated IGF2 methylation in newborn infants.

Recent evidence shows that DNA methylation patterns are reprogrammed genome-wide *in utero,* which result in stable changes in gene expression that may be maintained throughout a person's lifespan ([@R27]). The genomic imprints are established during the development of germ cells into sperms and eggs. After fertilization, the genomic imprints go through a resetting process, genome-wide demethylation after fertilization and *de novo* methylation after implantation([@R17]). While the underlying mechanisms for the *de novo* methylation *in utero* have yet to be fully established, maternal nutrition intake has been demonstrated to play a critical role in DNA methylation *in utero*. For example, studies of *in vitro* manipulation of human embryos have shown that environmental exposures during *in vitro* manipulation of early embryo induce DNA methylation alternations at imprinted loci, resulting in subsequent human diseases([@R3]; [@R4]; [@R16]). Using the Avy/a mice model, Wolff et al.([@R26]) found that the coat-color distribution of offspring born to dams supplemented with folic acid, vitamin B~12~, choline, and betaine was shifted toward the brown phenotype compared to those born to non-supplemented dams through increasing Avy methylation in the offspring([@R25]). In addition, maternal dietary exposure to folate alters the effects of adverse maternal environmental exposures on the DNA methylation changes of specific genes([@R9]).

One carbon metabolism, which ultimately provides the methyl groups for all DNA methylation reactions, is highly dependent on dietary methyl donors such as folate/folic acid and betaine and cofactors such as vitamins B~12~, B~6~, and B~2~, and zinc ([@R21]). Very few studies have been conducted to investigate whether maternal nutrition influences an offspring's DNA methylation patterns (Steegers-Theunissen et al., 2009). As such, we conducted a pilot study to examine the DNA methylation pattern of *IGF2* in cord blood and to examine whether maternal serum levels of folate and vitamin B~12~ influence IGF2 methylation pattern in cord blood.

SUBJECTS AND METHODS {#S6}
====================

Study Population {#S7}
----------------

A pilot study was conducted in Houzhai Center Hospital in Zhengzhou, China. Pregnant women, who were 19 years of age or older without pre-existing medical conditions such as diabetes, hepatitis B infection, or other coeliac diseases and who came to the hospital for delivery between April and September in 2008, were considered eligible for the study. All of the participants were from suburb close to Zhengzhou city. A total of 257 potentially eligible subjects were identified during the study time period. We reached potential eligible subjects who delivered babies from Mondays to Thursdays, which yield a total of 120 mothers. Among those, 99 (82.5%) were participated in the study with both maternal and cord blood available. Upon receiving their written consent, an in-person interview was conducted at the hospital using a standardized and structured questionnaire to collect information on demographic factors, maternal stature, medical conditions and medication use including supplemental vitamins, reproductive history, smoking and alcohol consumption, and dietary intakes. Two 5 ml fasting blood samples were provided by the subjects at the hospital before delivery. Blood was collected in red top vacuum tubes, and placed immediately on ice. After centrifugation, serum and white blood cells were separated and frozen at −70°C for subsequent analyses. Cord blood samples were also collected and processed using the same protocol. The birth weight, birth length and head circumference, and gestational age of newborns were abstracted from delivery room records. The study was approved by the Institutional Review Board at Zhengzhou University, China.

IGF2 Methylation Analysis {#S8}
-------------------------

Genomic DNA was extracted from blood samples (mother's blood and cord blood) using AxyPrep Blood Genomic DNA Miniprep kit (Axygen Biosciences, USA). The DNA samples were treated with sodium bisulfite using the EZ DNA Methylation-Gold^™^ kit (Zymo Research). CpG site methylation within two promoter regions of the IGF-II gene, P2 and P3, was analyzed using a Power SYBR Green PCR Master Mix (Applied Biosystems, UK) and real-time methylation specific PCR (qMSP) (MX3000, USA). Two qMSP assays, P2A and P3A, were developed to evaluate methylation in P2 and P3 regions ([@R2]). Each qMSP assay included two pairs of PCR primers; one for methylated and one for unmethylated bisulfite converted sequences. Primer sequences were referenced to the report by Beeghly et al. ([@R2]) and were listed in [Table 1](#T1){ref-type="table"}, along with annealing temperatures and product sizes. In [table 1](#T1){ref-type="table"}, the bold letters indicate bisulfite conversion of C to T.

In the PCR reaction (20 μL), 1 μL of bisulfite-treated DNA template with a proximate concentration of 100ug/ml was mixed with 10 μL of 2×Power SYBR Green PCR Master Mix (Applied Biosystems) and a pair of primers in a final concentration of 200 nmol/L. The PCR conditions included denaturing at 95 C for 10 min, and 40 cycles of denaturing at 94 C for 15s, annealing at 58 C or 59 C for 30s and extension at 72 C for 30s. After PCR amplification, a dissociation curve was generated to confirm the size of PCR product. Four quality control (QC) samples was included in each batch of methylation analysis, including two negative QC samples from untreated DNA and two water without DNA template.

Serum Folate Analysis {#S9}
---------------------

Serum folate was determined using a Folate Reagent kit (A14028, Beckman Coulter) and the paramagnetic particle chemiluminescent immunoassay system Access 2 analyzer (BECKMAN COULTER, USA). A standard curve was generated using the six calibrators included in the kit. All of the materials and reagents used for the test were provided by the Beckman Coulter Ins. We included one negative QC sample (contain human serum albumin buffer only) in each batch and one repeat in every 10 samples. The coefficients of variation (CV) for within- and between-run were 0.51 and 2.33% respectively.

Serum Vitamin B~12~ Analysis {#S10}
----------------------------

Serum vitamin B~12~ was determined using a B~12~ Reagent kit (A911973) and the paramagnetic particle chemiluminescent immunoassay system Access 2 analyzer (BECKMAN COULTER, USA). A standard curve was made by six calibrators which had vitamin B~12~ concentrations of 0, 106, 244, 493, 885, and 1,500pg/ml. All of the assay materials and reagents were provided by the Beckman Coulter Ins. We included one negative QC sample (contain human serum albumin buffer only) in each batch and one repeat in every 10 samples. The coefficients of variation (CV) for within- and between-run were 0 and 2.0% respectively.

Statistical Analysis {#S11}
--------------------

The methylation level was presented as a percentage of methylated sequences in all analyzed DNA sequences which was calculated based on the formula: $\text{M}/(\text{M} + \text{U}) \times 100\%$, where M is the copy number of methylated sequences and U is the copy number of unmethylated sequences. The above formula can be further expressed as $1/(1 + \text{U}/\text{M}) \times 100\% = 1/\lbrack 1 + 2^{- (\Delta\text{Ct})}\rbrack \times 100\%$, where ΔCt = Ct(U)-Ct(M). Ct is the threshold of PCR cycle number at which the increase in fluorescent signal reaches a critical point.

Levels of methylation at each promoter region were logarithmically-transformed to achieve approximately normal distribution and the transformed values were used in data analyses. The paired t-test was employed to compare serum levels of folate, vitamin B~12~, and methylation percentages between matched cord blood and maternal blood. Separate multivariate linear regression models were used to estimate the mean change (MC) in methylation percentages of IGF2 in cord blood in relation to an increase of one standard deviation in serum levels of folate and vitamin B~12~ in cord blood and mother's blood, and various maternal and neonatal characteristics including maternal age, maternal pre-pregnancy body mass index (BMI), maternal exposure to passive smoking (no active smoking in the study population), maternal education, maternal weight gain during pregnancy of index, parity, supplement intake during pregnancy of index, birth weight, birth length, gestational age, and baby's gender. The standard deviation for each characteristic was calculated from the entire study population. Multivariate linear regression model was also employed to estimate the MC in methylation percentages of IGF2 in mother's blood for an increase of one standard deviation in serum levels of folate and vitamin B~12~ in mother's blood, maternal age, maternal pre-pregnancy body mass index (BMI), maternal exposure to passive smoking, maternal education levels, maternal weight gain during pregnancy of the index, parity, and supplement intake during pregnancy of index. All statistical tests were two sided with 0.05 as a cutoff for significance. Statistical analyses were performed using the SAS software, version 9.1 (SAS Institute, Inc., Cary, NC).

RESULTS {#S12}
=======

As shown in [Table 2](#T2){ref-type="table"}, there were 99 newborns enrolled in the study (52 boys and 47 girls); of them, three had low birth weight (\<2,500g) and one was a preterm birth (\<37weeks). Forty percent of women in the study delivered by cesarean section and one third of them were not on their first parity. The mean maternal age was 27.8 years. A total of 13 women had BMI greater than 25 before pregnancy. About 30% women were exposed to passive smoking and 53% took supplementation (mainly includes calcium and traditional Chinese medicine) during pregnancy.

The mean levels of serum folate and vitamin B~12~ were 7.29ng/ml (range=0--21.0ng/ml) and 240pg/ml (range=78--1500ng/ml) in cord blood and 2.29ng/ml (range=0--11.2ng/ml) and 175pg/ml (range=57--1120ng/ml) in mother's blood respectively. The serum folate and vitamin B~12~ levels in cord blood were significantly higher than those in mother's blood (p\<0.0001). The serum levels of folate and vitamin B~12~ in cord blood and maternal blood were significantly correlated to each other (Pearson Correlation Coefficient=0.37, P=0.0003 for folate; Pearson Correlation Coefficient=0.31, P=0.0021 for vitamin B~12~).

The mean percentages of methylation in IGF2 promoter 3 (P3) were 5.83% (SD=4.92%, range=0.87--34.97%) for maternal blood and 4.11% (SD=3.04%, range=0.48--18.1%) for cord blood, and the percentage of methylation was significantly higher in maternal blood than in cord blood (p\<0.0001). In contrast, the mean percentages of methylation in IGF2 promoter 2 (P2) were 2.85% (SD=1.78%, range=0.11--10.1%) in maternal blood and 3.54% (SD=2.80%, range=0.53--18.7%) in cord blood, and the methylation percentage was significantly higher in cord blood than in maternal blood (p=0.016).

The mathylation patterns of P3 was significantly correlated between maternal and cord blood (Pearson Correlation Coefficient=0.41, P\<0.0001). Similar correlation, however, was not observed for P2 (Pearson Correlation Coefficient=0.19, P=0.06). The observed correlations were not changed when the analyses were stratified by maternal serum levels of folate. After stratification by maternal serum levels of vitamin B~12~, we found significant correlations of methylation patterns between maternal and cord blood for both P3 (Pearson Correlation Coefficient=0.43, P=0.0001) and P2 (Pearson Correlation Coefficient=0.27, P=0.02) when the levels were equal to or greater than 200pg/ml. No significant correlations were observed when maternal serum levels were equal to or greater than 200pg/ml.

Methylation of *IGF2* promoters in cord blood were not associated with serum levels of folate in either cord blood or mother's blood ([Table 3](#T3){ref-type="table"}). P3 methylation in cord blood appeared to be inversely associated with serum levels of vitamin B~12~ in maternal blood (MC=−0.22, p=0.0014) but not in cord blood (MC=−0.042, p=0.60). The association was diminished when the analyses were restricted to those who had maternal serum levels of folate ≥ 3ng/ml or vitamin B~12~ ≥ 200pg/ml (data not shown). No association with methylation in cord blood was found for maternal and neonatal characteristics.

P2 methylation in maternal blood were associated with mother's vitamin B~12~ levels (MC=−0.23, p=0.012), exposure to passive smoking (MC=0.46, p=0.034) and weight gain during pregnancy (MC=0.23, p=0.019 [Table 3](#T3){ref-type="table"}), while no significant association was observed for P3 methylation in mother's blood.

DISCUSSION {#S13}
==========

The *IGF2* gene contains four promoters (P1--P4) located upstream of exons 1, 4, 6, and 7 respectively ([@R5]). Each of the promoters can initiate transcription giving rise to a family of transcripts with distinct 5′-untranslated regions ([@R22]). Since these transcripts differ in their translatability and stability ([@R6]; [@R13]; [@R14]), the resulting IGF2 protein may vary in terms of quantity. The usage of *IGF2* promoters has been shown to be both temporal and tissue specific with P2--P4 active in all fetal tissues and P1 only active in the healthy adult liver ([@R6]). While the first promoter (P1) contains few CpG sites, the latter three promoters (P2--P4) exist in a large CpG rich region ([@R2]; [@R7]). Because the P4 has been found to have the lowest frequency of methylation among the three promoters in our previous study ([@R2]), we focused on P2 and P3 promoters in this pilot study.

We found a strong correlation of P3 methylation between maternal and cord blood, but the correlation was diminished when the maternal serum levels of vitamin B~12~ were within the normal range. A strong correlation of P2 methylation between maternal and cord blood was observed only among those who had maternal serum levels of vitamin B~12~ lower than the normal range. These results might suggest a stronger heritable nature of methylation when maternal vitamin B~12~ was low. In another word, higher maternal vitamin B~12~ could alter inherited methylation patterns. Because the maternal serum levels of folate and vitamin B~12~ in this study population was relatively low with 71% of the population having serum levels of folate less than 3ng/ml and 75% of the population having vitamin B~12~ less than 200pg/ml, the sample size were limited in the stratified analyses particularly for those who had higher levels.

In this pilot study, the methylation patterns of P3 in cord blood were negatively associated with serum levels of vitamin B~12~ in maternal blood. No association was observed between methylation patterns and serum folate levels in either mother's blood or cord blood. The higher percentages of population had normal concentration in cord blood for folate than for vitamin B~12~ (83% vs. 35%) might be a possible explanation. In addition, the levels of folate and vitamin B~12~ were much higher in cord blood than in mother's blood suggesting that the enrichment of necessary one carbon nutrients ensures the development of infants even in a very low concentration. On the other hand, the inconsistent findings for P2 and P3 in cord blood may suggest that influence on *de novo* methylation is likely to be promoter or CpG site dependent.

The methylation patterns in mother's blood were negatively associated with serum levels of vitamin B~12~ but not folate, and the association was only observed for P2. We also observed that mother's *IGF2* P2 methylation status was associated with exposure to passive smoking and weight gain during pregnancy. Weight gain during pregnancy reflects complex endogenous and exogenous factors such as nutrition, energy intake, physical activity, individual's metabolic rate, and certain underlying diseases, etc. It is difficult to delineate specific endogenous or environmental factors underlying the observed association. However, the results suggest that mother's methylation status can be affected by environmental factors.

One of the limitations of the study is that none of the study subjects took folic acid supplements before or during pregnancy, which limited our ability to examine the effect of folic acid supplementation. Since serum folate and vitamin B~12~ concentrations reflect the balance of folate and vitamin B~12~ intake from diet and other resources, their absorption and excretion, using serum concentrations is more reliable compared to using the data of dietary intake from questionnaire. Since the majority of study participants had serum levels of folate or vitamin B~12~ in the lower end of the normal range (defined as \<3ng/ml for folate and 200pg/ml for vitamin B~12~), which is comparable with the levels in populations who lived in the areas without food fortification program ([@R8]; [@R19]; [@R24]). As such, the results of our study may not be generalizable to populations with high levels of folate or vitamin B~12~.

DNA methylation patterns are tissue specific. DNA derived from peripheral blood cells are mainly from neutrophils, eosinophils, lymphocytes, and monocytes, which are likely to have different methylation profiles from those of other tissues ([@R12]). The inconsistent results between maternal blood and cord blood observed in the current study could be due to different composition of individual celltypes between maternal and cord blood. It is important that celltypes are controlled in future studies.

In conclusion, the study provides the first human evidence that heritable nature of and environmental influences on methylation patterns are not uniform across different promoters within the same gene. Given the lack of understanding of methylation status in newborns and factors that influence *de novo* methylation, studies using a genome-wide approach to identify DNA methylation patterns of CpG islands in newborns and factors that are responsible for *de novo* methylation are needed.
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###### 

MSP primer sequences, annealing temperatures, and product size summary

  prime[\*](#TFN1){ref-type="table-fn"} r   Primer sequence 5′→3′                                           T~a~(°C)   Product(bp)
  ----------------------------------------- --------------------------------------------------------------- ---------- -------------
  *P*2A, *M*, *F*                           CGGA**TT**T**TTT**ACGCGGGGA**T**CG                              59         127
  *P*2A, *M*, *R*                           CCGA**A**CTTA**A**CG**AA**CGTCCG                                           
  *P*2A, *U*, *F*                           G**TT**TG**T**GGA**TT**T**TTT**A**T**G**T**GGGGA**TT**G                    137
  *P*2A, *U*, *R*                           **A**CA**M**CCC**A**A**A**CTTA**A**C**AAA**C**A**TCC**A**                  
  *P*3A, *M*, *F*                           CG**T**AG**T**CGG**TT**TT**T**CGCGCG                            58         149
  *P*3A, *M*, *R*                           CG**AA**CG**AAA**CGCGCA**A**CCG                                            
  *P*3A, *U*, *F*                           **T**GG**T**G**T**AG**TT**GG**TT**TT**TT**G**T**G**T**GT**T**              159
  *P*3A, *U*, *R*                           CCT**AAA**CAC**AAA**C**AAAA**C**A**C**A**CA**A**CC**A**                    

Primer name: *P* means promoter region, *M* methylated, *U* unmethylated, *F* forward, *R* reverse

###### 

Selected characteristics of mothers and newborns (n=99)

  Newborn's characteristics                    Number   Mean (Standard Deviation)   Range
  --------------------------- ---------------- -------- --------------------------- --------------
  Birth weight                \<2,500g         3                                    
                              2,500g--4,000g   93       3,200 (400)                 2,100--4,300
                              \>4,000g         3                                    
  Birth length                \<50cm           42                                   
                              50cm             28       49.5 (1.9)                  42--53
                              \>50cm           29                                   
  Head circumference          \<34cm           30                                   
                              34cm             47       33.8(1.2)                   29--38
                              \>34cm           22                                   
  Gestational age             \<37weeks        1                                    
                              37--41weeks      96       39.1 (1.1)                  36--43
                              ≥42weeks         2                                    
  Gender                      Boy              52                                   
                              Girl             47                                   
  Caesarean birth             Yes              41                                   
                              No               58                                   

  Mother\'s characteristics                                                            Number   Mean (Standard Deviation)   Range
  ------------------------------------------------------- ---------------------------- -------- --------------------------- ------------
  Age                                                     \<25 years                   35                                   
                                                          25--29 years                 25                                   
                                                                                                27.8 (5.3)                  19--37
                                                          30--34 years                 29                                   
                                                          35+ years                    10                                   
  Height                                                  \<160cm                      44                                   
                                                          160--164cm                   34       159.5(5.1)                  140--170
                                                          165cm+                       21                                   
  Pre-pregnancy BMI                                       \<20                         37                                   
                                                          20--25                       49       21.4(2.6)                   14.7--28.3
                                                          \>25                         13                                   
  Weight gain during pregnancy                            \<10kg                       9                                    
                                                          10--20kg                     85       14.6 (3.6)                  5--22.5
                                                          \>20kg                       5                                    
  Highest education level                                 Elementary school            18                                   
                                                          Middle school                57                                   
                                                          High school                  19                                   
                                                          College or graduate school   5                                    
  Passive smoking                                         Yes                          30                                   
                                                          No                           69                                   
  Number of live births[1](#TFN2){ref-type="table-fn"}    1                            68                                   
                                                          2                            26                                   
                                                          \>2                          5                                    
  Supplementation intake[2](#TFN3){ref-type="table-fn"}   Yes                          53                                   
                                                          No                           46                                   

The number of live births included the current birth.

The supplements included calcium and the traditional Chinese medicine.

###### 

Associations between methylation status and serum folate and vitamin B~12~ levels

                                                                                  MC[1](#TFN4){ref-type="table-fn"}   P-value
  ------------------------------------------------------------------------------- ----------------------------------- ---------
  **Cord blood**[2](#TFN5){ref-type="table-fn"},[3](#TFN6){ref-type="table-fn"}                                       
  Promoter P2                                                                                                         
   Cord blood serum folate                                                        0.18                                0.065
   Cord blood serum vitamin B~12~                                                 −0.027                              0.75
   Maternal blood serum folate                                                    0.052                               0.47
   Maternal blood serum vitamin B~12~                                             0.094                               0.19
  Promoter P3                                                                                                         
   Cord blood serum folate                                                        −0.027                              0.77
   Cord blood serum vitamin B~12~                                                 −0.042                              0.60
   Maternal blood serum folate                                                    0.049                               0.47
   Maternal blood serum vitamin B~12~                                             −0.22                               0.0014
  **Mother\'s blood**[4](#TFN7){ref-type="table-fn"}                                                                  
  Promoter P2                                                                                                         
   Maternal serum folate                                                          0.13                                0.17
   Maternal serum vitamin B~12~                                                   −0.23                               0.012
   Maternal exposure to passive smoking                                           0.46                                0.034
   Weight gain during pregnancy                                                   0.23                                0.019
  Promoter P3                                                                                                         
   Maternal serum folate                                                          0.13                                0.15
   Maternal serum vitamin B~12~                                                   −0.096                              0.25

Mean change per standard deviation of each characteristic.

The multivariate linear regression model also included mother's age, maternal pre-pregnancy BMI, weight gain during pregnancy, mother's highest education level, parity, supplementation intake during pregnancy, baby's birth weight and birth length, baby's gender, and gestational age.

Separated models were run for the folate and vitamin B~12~ levels in maternal and cord blood.

The multivariate linear regression model also included mother's age, mother's pre-pregnancy BMI, mother's highest educational level, parity, and supplementation intake during pregnancy.
